“Adalimumab Efficacy in Hidradenitis Suppurativa Patients Is Sustained at Least Three Years With Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s128. https://doi.org/10.25251/skin.1.supp.127.